Table 1 Clinical and biochemical characteristics of RDN patients and DC
From: The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation
RDN n = 10 | DC n = 4 | P values | |
|---|---|---|---|
Sex, female % | 28 | 25 | n.s. |
Age, years | 61.5 (47.4–71.3) | 66.5 (58.7–75.7) | n.s. |
P-hsCRP mg/ml | 2.5 (0.5–7.8) | 2.5 (1.9–4.7) | n.s. |
B-Hb g/L | 139.5 (131.6–157.6) | 134.5 (127.9–139) | n.s. |
B-WBC × 109/L | 7.6 (6.6–11.9) | 5.6 (5.0–8.9) | n.s. |
B-Neutrofils × 109/L | 4.4 (2.6–6.6) | 3.0 (2.4–5.0 | n.s. |
B-Lymphocytes × 109/L | 2.7 (1.5–3.4) | 2.0 (1.4–3.0) | n.s. |
B-Monocytes × 109/L | 0,7 (0.5–1.0) | 0.6 (0.4–0.8) | n.s. |
P-Creatinine μmol/L | 96.5 (79.4–156.7) | 83.5 (65.6–144.1) | n.s. |
Systolic blood pressure, mmHg, mean | 180 | 148 | n.a. |
Diastolic blood pressure, mmHg, mean | 100 | 75 | n.a. |
Anti-hypertensive medication, mean | 4 | 3 | n.a. |
Diuretics % | 90 | 25 | n.a. |
ACE- inhibitor % | 80 | 75 | n.a. |
ARB % | 40 | 25 | n.a. |
Ca- channels blocker % | 90 | 25 | n.a. |
Beta-blocker % | 100 | 75 | n.a. |
Alfa- blocker % | 10 | 0 | n.a. |